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This study demonstrates the
diagnostic value and predic-
tive potential of lobulated
enhancement occurrence in
assessing local progression
of liver metastases treated by
stereotactic body radiation
therapy. The treatment of
patients could be improved
by the earlier detection of
local progression at a time
when the lesion size is still
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http://dx.doi.org/10.1016/j.ijrobp.2015.01.028Objective: The Response Evaluation Criteria in Solid Tumors (RECIST) can have limi-
tations when used to evaluate local treatments for cancer, especially for livermalignancies
treated by stereotactic body radiation therapy (SBRT).Theaimof this studywas tovalidate
the relationship between the occurrence of lobulated enhancement (LE) and local relapse
and to evaluate the utility of this relationship for predicting local progression.
Patients andMethods: Imaging data of 59 lesions in 46 patients, including 281 computed
tomographic (CT) scans, were retrospectively and blindly reviewed by 3 radiologists. One
radiologist measured the lesion size, for each CT and overall, to classify responses using
RECIST threshold criteria. The second studied LE occurrence. A third radiologist was
later included and studied LE occurrence to evaluate the interobserver consistency for
LE evaluation.
Results: The mean duration of follow-up was 13.6 months. LE was observed in 16 of
18 progressive lesions, occurring before size-based progression in 50% of cases, and the
median delay of LE detection was 3.2 months. The sensitivity of LE to predict progres-
sion was 89%, and its specificity was 100%. The positive predictive value was 100%,
the negative predictive value was 95.3%, and the overall accuracy was 97%. The prob-
ability of local progression-free survival at 12 months was significantly higher for le-
sions without LE compared with all lesions: 0.80 (CI 95%: 0.65-0.89) versus 0.69
(CI 95%: 0.54-0.80), respectively. The overall concordance rate between the 2 readers
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by including LE. This study demonstrates the diagnostic and predictive utility of LE for
assessing local progression at a size still eligible for local salvage treatment.  2015
The Authors. Published by Elsevier Inc. This is an open access article under the CC
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Robotic stereotactic body radiation therapy (SBRT) is a
technique that allows delivery of a high radiation dose to a
tumor while sparing adjacent normal tissues. This is ach-
ieved by using a respiratory tracking system that enables
accurate radiation delivery, even while the patient breathes
freely (1). This technique is an additional therapeutic op-
tion for inoperable liver metastases (2) and has been shown
to result in favorable liver tolerance and good response
rates (3-6).
Monitoring the response of liver metastases to SBRT
with imaging is of utmost importance because the misin-
terpretation of changes detected by imaging may cause a
delayed diagnosis of recurrence or may subject the patient
to unnecessary chemotherapy.
Assessment of treatment outcomes in solid tumors is
usually determined by Response Evaluation Criteria in
Solid Tumors (RECIST) (7) based on 1-dimensional
tumor size. However, these criteria have limitations for
the evaluation of targeted therapies; for example, imatinib
for gastrointestinal stromal tumors (GIST) and bev-
acizumab for colorectal liver metastasis (8-10) or other
local treatments, such as lung tumor SBRT (11), liver
radiofrequency ablation (12), and hepatocellular carci-
noma treated by SBRT (13). Some authors have suggested
that the use of functional imaging allows for earlier and
more accurate assessment of response to different
treatments when compared with morphologic responses:
18F-fluorodeoxyglucose positron emission tomography
(18FDG-PET), computed tomographic (CT) perfusion,
diffusion-weighted sequences, and contrast ultrasound)
(14-17); however, further work is needed to standardize
the procedures for widespread use. A previous study,
conducted in our center, focused on the posttherapeutic
CT imaging features of hepatic metastasis treated by
SBRT and identified new criteria of early response and
progression by incorporating morphologic changes into a
size-based response (18). For progressive lesions, the
appearance of a lobulated, irregular, thick, peripheral
enhancement was observed. This morphologic pattern,
called lobulated enhancement (LE), is easy to identify by
contouring the outline of a lesion (Fig. E1, available on-
line at www.redjournal.org).
The aim of this study was to validate the relationship
between the occurrence of LE and local response and to
evaluate the utility of this relationship in the diagnosis and
prediction of local progression.Patients and Methods
Patients with liver metastases who were ineligible for
surgery or radiofrequency ablation and who were referred
to our center for SBRT radiosurgery were included.
Treatment indication was approved in a multidisciplinary
staff meeting that included a hepatic surgeon, a radiation
oncologist, a medical oncologist, and an interventional
radiologist. The following criteria were used: World
Health Organization performance status score less than 3,
4 or fewer hepatic lesions, and initial lesion size smaller
than 100 mm. The delivered radiation dose was 40 Gy
in 4 fractions initially, then it increased to 45 Gy in 3
fractions.
The inclusion criteria for this study were as follows:
patients with liver metastases treated by SBRT with respi-
ratory tracking, target lesion size of at least 10 mm
(according to RECIST criteria), and at least a 6-month
delay between the first treatment session and the latest
follow-up CT scan. CT scans were obtained with a
16-detector row CT scanner (Sensation 16; Siemens AG,
Munich, Germany) until 2010 and then with a 128-detector
row CT scanner (Somatom Definition AS; Siemens AG).
The exclusion criteria were as follows: lobular shaped
lesion at the pretherapeutic CT scan making LE difficult to
detect (evaluated during a first review by a senior radiolo-
gist) and lack of sufficient follow-up CT examinations (with
at least 1 portal phase), including a pretherapeutic CT scan
and at least 2 posttherapeutic examinations.
This study was approved by our internal review board,
and informed consent was obtained from all referred
patients.
A blinded retrospective review of CT examinations was
performed by 2 radiologists. One radiologist measured the
longest diameter and recorded lesion size in an edited
reading grid. The second studied the lesion’s shape and
recorded lesion morphology in a second edited reading grid
using 1 of 3 possible descriptors for each lesion at each CT:
LE-present, LE-absent, or LE-doubtful. LE was defined as
a thick (>1 mm) peripheral LE that included at least 3
lobulations. A typical LE is shown in Figure 1.
Posttherapeutic local outcome was classified into 4 cat-
egories according to the RECIST threshold criteria for each
hepatic lesion: local complete response (LCR) with the
disappearance of the treated hepatic lesion, local partial
response (LPR) with more than a 30% decrease from the
baseline of the longest irradiated lesion diameter, local
progressive disease (LPD) with more than a 20% increase
Fig. 1. Enhanced computed tomographic scans at portal phase axial views of a 69-year-old woman with a liver metastasis
from colon cancer treated by SBRT. (a) Before treatment. (b) At 3.7 months. (c) At 5.8 months. (d) At 9.3 months after
treatment. Typical lobulated enhancement occurred at 3.7 months, with a peripheral thick lobulated enhancement that looked
like a daisy (b), with an increased number of lobulations and lesion size on next follow-up scans.





TotalLPD LSD LPR LCR
Present 0 27 9 0 0 36
Doubtful 0 1 1 0 0 2
Absent 59 4 92 75 13 243
Total 59 32 102 75 13 281
Abbreviations: LCR Z local complete response; LPD Z local
progressive disease; LPRZ local partial response; LSDZ local stable
disease.
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local stable disease (LSD).
The overall response for each lesion was ranked as LPD
if this status occurred once during follow-up. Otherwise, it
was ranked as best quoted response (LPR, LSD, or LCR)
during follow-up.
All of the CT evaluations were assessed independently
by another radiologist for the presence or absence of LE.
The assessor was blinded to the results of the first evalua-
tion. Statistical analysis was performed with the Stata sta-
tistical software package, version 11.2 (StataCorp LP,
College Station, TX). The demographics and lesion char-
acteristics are presented as frequencies and percentages.
The association between the occurrence of LE and local
response was assessed by Pearson c2 test. Initial lesion
size was compared between LE-present and LE-absent or
LE-doubtful groups and between progression and local
control groups by the Mann-Whitney U test. Quantitative
variables were compared between predictive LE and non-
predictive LE groups by the Mann-Whitney U test.
Local progression-free survival (LPFS) was defined as
the time from the start of treatment until the criteria for
local progression of an irradiated lesion was met. Lesions
that met the criteria for progression were censored at the
last follow-up visit. The LPFS rates were estimated by the
Kaplan-Meier method. The LPFS curves were analyzed
separately for all lesions and lesions without LE to account
for the censoring of lesions with LE occurrence at the time
of their observation. The impact of LE on LPFS was tested
by the use of time-dependent covariates in a Cox propor-
tional hazards model. Response rates are presented with a
95% confidence interval calculated from the binomial dis-
tribution. Differences were considered statistically signifi-
cant when P<.05.
Concerning LE concordance, the McNemar test was
used to test for symmetry among the discordant pairs, and
the k statistic was used to assess agreement.Results
Between July 2007 and September 2011, 128 patients
were treated by SBRT for liver metastasis; 82 patients
were excluded from this study, 80 for lack of sufficient
follow-up and 2 for initial lobulated shape. Fifty-nine
lesions in 46 patients were analyzed (Table E1, available
online at www.redjournal.org). The median age was 65
(range, 23-84 years), and 35% were female. The primary
cancer sites were colorectal (63%), breast (9%), and other
sites (28%). The median initial lesion size was 30.5 mm
(range, 11-83 mm). Thirty-six (78%) patients presented
with only 1 lesion.
Two hundred eighty-one CT examinations were
reviewed by 2 radiologists: 59 before treatment and 222
after treatment.
Pretherapeutic CT scans were performed 20  14 days
before the treatment started. The mean duration of CT im-
aging at follow-up was 13.6  5.8 months, with a follow-up
duration of more than 9 months for 73% of the lesions.
Size-based local response and morphologic features,
evaluated after each CT scan, are presented in Table 1.
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classified as partial or complete response. A total of 15
lesions showed a discordant association between LE clas-
sification and size-based response. Nine size-based local
responses classified as LSD/LE-present included 8 lesions
that later had a size-based local progression and thus had a
LE classification that was predictive of outcome. Four size-
based local responses classified as LPD/LE-absent and 2
classified as LE-doubtful represented 2 lesions from 1 pa-
tient that were LE-doubtful at 3.8 months but were not
confirmed later when size-based progression occurred. The
characteristics of these 2 lesions evolved similarly with a
pattern of increase that is associated with nonenhanced
lesions and is indicative of total necrosis (Fig. E2, available
online at www.redjournal.org).
The overall responses for all lesions are presented in
Table 2, where each lesion has an overall response in size
ranked as LPD if this status occurred once during follow-
up. Otherwise, it was ranked as best quoted response
(LPR, LSD, or LCR) during follow-up. LE status is re-
ported for each lesion as well.
The local progression rate was 30.5% (18/59), and the
mean delay before progression was 8.5  3.3 months
(range, 3.8-19.1 months).
Among the 18 progressive lesions, LE occurred during
follow-up in 16 cases (90%). Among these 16 LPD/LE-
present cases, LE appeared before size-based progression
and thus was predictive of progression in 8 of 16 (50%) of
cases. An example is shown in Figure E3 (available online
at www.redjournal.org). These 8 predictive cases corre-
sponded to the 9 LSD/LE-present cases in Table 1 (for 1
lesion, LE was observed twice before progression
occurred). For the 8 remaining cases, LE appeared at the
same time as progression. No LE appeared after local
progression. No patient categorized as having a progressive
lesion changed their response status after progression
occurred. For all lesions with LE present (nZ16), no
reversal was observed; however, an increase in the number
of lobulations and thickness of enhancement was observed.
Two cases of progression without LE were observed in 1
patient, corresponding to the 2 LE-doubtful cases and the 4
LPD/LE-absent cases (Table 1).
Lesions considered as in local control (41/59) included 6
LCR, 26 LPR, and 9 LSD. No LE was observed in these 41Table 2 Size-based overall response and lobulated
enhancement status during follow-up
Lobulated enhancement
Size-based overall response
TotalLPD LSD LPR LCR
Present 16 0 0 0 16
Doubtful 2 0 0 0 2
Absent 0 9 26 6 41
Total 18 9 26 6 59
Abbreviations: LCR Z local complete response; LPD Z local
progressive disease; LPRZ local partial response; LSDZ local stable
disease.lesions during follow-up. There was no significant differ-
ence in initial lesion size between LPD and local control
groups (PZ.32).
There was no significant difference in initial lesion size
between groups LE-present and LE-absent or LE-doubtful
(PZ.17).
A significant association between the occurrence of LE
and size-based progression (Table 3) was observed. The
sensitivity of LE to predict a progression was 89% (16/18),
and its specificity was 100% (41/41). The positive predic-
tive value was 100% (16/16), and the negative predictive
value was 95.3% (41/43), for an overall accuracy of 97%
(57/59). In 50% of progressive lesions (8/16), LE occurred
before local size-based progression.
The characteristics of lesions with LE are summarized in
Table 4. The median time to LE occurrence was 6.4 months
(range, 2.4-19.1 months). The median size at LE occur-
rence was 38.5 mm (range, 18-96 mm). For predictive cases
(nZ8), the median time to LE occurrence was 3.9 months
(range, 2.4-9.0 months), the median time of prediction
before progression was 3.2 months (range, 1-6.9 months),
and the median size at LE occurrence was 32.5 mm (range,
18-52 months).
There was no significant difference between predictive
and nonpredictive LE groups for the following variables:
lesion size at size-based progression (PZ.96), initial size
(PZ.83), and time to local progression (PZ.88).
The delay between the beginning of the treatment and
the last CT scan, performed before LPD, was significantly
shorter in the predictive LE group than in the nonpredictive
LE group (PZ.02) (Table 4).
The probability of survival without local progression
was estimated for 2 groups: all lesions and lesions without
LE (lesions were censored when LE occurred) (Fig. 2). A
significant difference was found between these groups
when LE was used as a time-dependent covariate in a Cox
model (P<.0001), indicating that progression is more likely
to occur when LE appears during follow-up.
The probability of local progression-free survival at
12 months was lower for all lesions compared with lesions
without LE: 0.69 (confidence interval [CI] 95%: 0.54-0.80)
versus 0.80 (CI 95%: 0.65-0.89), respectively.
For interobserver variability, a total of 275 of 281 as-





LE Present before or when LPD 16 0 16
LE Absent or doubtful 2 41 43
18 41 59
Abbreviations: LCR Z local complete response; LE Z lobulated
enhancement; LPD Z local progressive disease; LPR Z local partial
response; LSD Z local stable disease.
Table 4 Characteristics compared according to predictive value of lobulated enhancement pattern
Characteristic
All LE (nZ16) Predictive LE (nZ8) Nonpredictive LE (nZ8)
Median (min-max) Median (min-max) Median (min-max)
Size, mm
Initial size 30.5 (16-83) 32 (16-67) 27.5 (16-83)
Size at first LE 38.5 (18-96) 32.5 (18-52) 49 (25-96)
Size at LPD 43.5 (21-96) 42.5 (21-95) 49 (25-96)
Delay, mo
Time to LPD 8.1 (4.8-19.1) 8.5 (4.8-12.3) 8.1 (6.3-19.1)
Time to first LE 6.4 (2.4-19.1) 3.9 (2.4-9)* 8.1 (6.3-19.1)*
Delay of last CT performed before LPD 3.6 (2.1-12.4) 3 (2.1-4.5)* 5 (2.8-12.4)*
Abbreviations: CTZ computed tomography; LEZ lobulated enhancement; LPDZ local progressive disease; maxZ maximum; minZ minimum.
* P<.05.
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absent by the first LE assessor were evaluated as present,
and 2 evaluations initially coded as present by the first LE
assessor were evaluated as absent at the same time point
(McNemar, PZ.68). The k statistic was equal to 0.91
(P<.0001), indicating close to perfect agreement.
Considering the presence of LE for each lesion, there
was 100% concordance. The 6 discordant cases concerned
only the time to observation of LE that occurred at the
previous assessment 1.5, 2.6, 4.7, and 5.3 months earlier (4
lesions) and at the next assessment 2.4 and 4.3 months later
(2 lesions) for the second assessor.Discussion
Because of the high conformity index and the use of a
respiratory tracking system, SBRT can deliver a high dose
of radiation to a precise target volume. The planning target
volume includes the gross target volume and a 5-mm pe-
ripheral expansion that represents the microscopic exten-
sion of disease (clinical target volume) plus an additional
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Fig. 2. Local progression-free survival according to the
predictive value of the lobulated enhancement (LE) pattern.The irradiated volume is larger than the tumor volume,
creating a region where fibronecrotic scar tissue could form
and whose monitoring is not relevant with RECIST criteria
because a tumor response may be achieved with a stable
target, and conversely recurrence from a residual viable
peripheral portion may occur while size criteria achieve
stable disease. The challenge for follow-up imaging is to
detect as early as possible this viable peripheral tumor
portion, which may lead to treatment failure, at a stage
when additional local treatment is still possible.
The focus of this study was on the pattern of occurrence
of LE, a posttherapeutic morphologic feature of liver me-
tastases treated by SBRT, and the diagnostic and prognostic
utility of this pattern.
The RECIST criteria are widely used to assess response
to treatment. However, this response assessment has limits,
as has already been reported, especially for response
assessment of hepatocellular carcinoma and pulmonary
lesions treated by SBRT and liver metastases treated by
radiofrequency ablation.
Posttherapeutic features of liver metastases treated by
SBRT make response assessment with the use of interna-
tional standardized criteria often inadequate.
In this study, we describe a prospective marker of local
progression in liver metastases treated by SBRT. Our results
demonstrate a significant association between LE occurrence
and size-based progression. The prevalence of local pro-
gression in this study is similar to that in other published
studies. Our rate of local control at 1 year was 69% compared
with the 71% of Lee et al (19), the 72% of Kress et al (5), and
the 73% of Dewas et al (20). The sample of lesions included
in this study can therefore be considered representative. LE
was observed in 90% of progressive lesions. Two false
negative LE cases, which occurred in 2 lesions from the same
patient, had an increase in size with a doubtful LE at
3.8 months after treatment, but this was not confirmed later.
Although progression was considered to be significant ac-
cording to RECIST criteria cut-offs, these 2 lesions showed
no LE, suggesting the presence of total necrosis and a
pseudoprogression response. Similar response features have
been describedwith targeted therapies, such as for GIST liver
metastases treated by imatinib (21) and colorectal hepatic
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uted the increased lesion size to a hemorrhagic phenomenon,
cystic degeneration, and intratumoral necrosis. Biopsies of
the 2 LPD/LE-absent lesions were not performed because of
an extrahepatic progression (cerebrum) and the absence of
additional therapeutic options for the patient.
No LE occurred during follow-up in local control le-
sions. For progressive lesions, 5 of 18 were classified as PR
at the beginning of follow-up. Therefore, an initial PR at
3 months does not exclude the possibility of later pro-
gression. This emphasizes the importance of follow-up and
the potential prognostic value of LE occurrence and
detection as a predictor of progression, particularly because
no biomarker predictive of response is currently in use for
liver metastases treated by SBRT. LE was predictive of
progression in 50% of cases (8/16), and the median delay of
prediction was 3.2 months.
The median delay between the last CT follow-up and the
occurrence of progression was significantly shorter in the
predictive LE group (3 months) than in the nonpredictive
LE group (5 months). This highlights the challenges to
having a homogeneous follow-up for all patients, given the
potential for geographic breakdown leading to a decen-
tralized follow-up. A heterogeneous follow-up likely
affected the percentage of predictive LE, and a more reg-
ular follow-up could have maximized the rate of predictive
cases. Further studies would help to confirm this.
The median size of lesions when LE was first observed
was smaller in the predictive LE group than in the non-
predictive LE group, allowing for additional local treatment
to be considered for the predictive LE group. Integrating LE
into the imaging evaluation could optimize patient treatment
by enabling local salvage therapy at the time when LE is
observed, while the lesion is still eligible for local therapy by
either reirradiation (23) or radiofrequency ablation (24).
Based on our analysis of the mean delay before progres-
sion occurrence (8.5 months) and LPFS curves, adjustments
to CT follow-up that include shorter time intervals between
follow-up scans (for example, between 3 and 6 months or at
4.5months) in the first year for patients with LEwould ensure
detection of recurrences as early as possible.
A limitation of this study was that 80 patients were
excluded for lack of sufficient follow-up data. Some of
these patients were not followed up in our center, making
collection of their data difficult. Centralization of follow-up
is a constraint for patients recruited far from the region.
Although 25 of the 80 excluded patients had multimodal
follow-up, using alternately CT, MRI, or FDG-PET, we
chose not to integrate data from multiple modalities to
ensure homogeneous data and measurements.
In this study, we excluded lesions with an initial lobu-
lated shape (2 patients) because this would make the
detection of LE difficult. For the imaging of those lesions to
assess a response, a combination of criteria was used based
on a previous study (18): lesion size, LE, and total necrosis.
Functional quantitative imaging techniques such as
diffusion-weighted sequences, perfusion MRI, or PETcould facilitate response assessment in these lesions
(14, 16, 25-27).
Although a minimum follow-up time of 6 months seems
insufficient for SBRT evaluation, 73% of lesions in this
study were followed up for more than 9 months, and the
mean duration of follow-up, 13.6 months, was similar to
that in published studies (20, 28).
The RECIST criteria were used to evaluate lesions for 2
reasons. First, histopathologic confirmation was unavailable
and often was not justified because it would not change
patient treatment; second, this response assessment of liver
tumors treated by SBRT, which is based on size criteria, has
been used in published studies and is currently used in
multicenter studies (3, 20, 28).
The use of RECIST criteria for other local treatments,
such as radiofrequency ablation (12), is questionable
because SBRT destroys a target volume that is larger than
the tumor volume and includes a peripheral margin of
surrounding “healthy” tissue, resulting in scar tissue that
progressively shrinks. Size measurement alone provides
insufficient information because it does not include
important posttherapeutic changes, such as tumor necrosis,
LE, and tumor metabolic changes (25). The use of CHOI,
mRECIST, and EASL criteria may be questionable but they
seem to be inadequate for early detection of progression in
liver metastases treated by SBRT for 2 reasons. First, liver
metastases that are eligible for SBRT in our study have
already been modified by previous chemotherapy and thus
do not show internal enhancement but peripheral and
circumferential enhancement whose measurement consists
finally in the measurement of the total size of the tumor.
Second, monitoring the thickness of peripheral enhance-
ment may not be appropriate in the case of SBRT because it
includes the surrounding focal liver reaction related to
radiation injury. Thus, the shape of enhancement is an
important pattern and could make differentiating recurrence
from radiation injury easier (18).
The use of PET FDGCTmay be promising if it is borne in
mind that radiation injury surrounding the lesion may show
an increased uptake. An increase of the standard uptake value
during follow-up may be helpful in the discrimination of
local progression, but this implies the availability of PET for
monitoring liver metastasis after SBRT.
The LE is an easily reproducible sign (concordance rate
97.9%, kZ0.91 [P<.0001]). The interobserver variability
concerned time to observation of LE (earlier for second LE
assessor in 4 cases and later in 2 cases compared with the
first LE assessor). This variability is explained by the
subtlety of LE at the beginning (at least 3 lobulations,
thickness >1 mm).
Given the promising potential of LE in the diagnosis and
prediction of local progression in liver metastases, it should
be incorporated with combined criteria for assessing tumor
response after SBRT.
It is concluded that SBRT is an option for the local
treatment of unresectable liver malignancies, especially
liver metastases. Response assessment using imaging
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as demonstrated in this study, this could be optimized by
including an evaluation for LE. This study demonstrates the
diagnostic value and predictive potential of LE occurrence
in assessing local progression and the high interobserver
concordance rate of this sign. Patient treatment could be
improved by the earlier detection of local progression at a
time when the lesion size is still eligible for local salvage
treatment. On the basis of the results of this study, we
recommend that additional CT examinations be performed
between 6 and 9 months to optimize patient treatment.References
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